These pathways mainly involve the dysfunction and downregulation of T cell proliferation, impaired antigen-specific response, reduced natural killer cell count, upregulation of IL-17 production, tumor escape and tolerogenicity (Figure 12A, Supplementary Figure 1). The gene discussed is IL17A; the disease is neoplasm.